Last reviewed · How we verify

Gabapentin Enacarbil (GEn)

Cleveland Sleep Research Center · FDA-approved active Small molecule

Gabapentin enacarbil is a prodrug of gabapentin that enhances GABA neurotransmission in the central nervous system by increasing inhibitory signaling.

Gabapentin enacarbil is a prodrug of gabapentin that enhances GABA neurotransmission in the central nervous system by increasing inhibitory signaling. Used for Restless legs syndrome (RLS), Postherpetic neuralgia (PHN).

At a glance

Generic nameGabapentin Enacarbil (GEn)
Also known asHORIZANT
SponsorCleveland Sleep Research Center
Drug classGabapentinoid; anticonvulsant/neuropathic pain agent
TargetVoltage-gated calcium channel alpha-2-delta subunit
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Gabapentin enacarbil is converted to gabapentin in vivo and binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing excitatory neurotransmitter release. This mechanism reduces neuronal hyperexcitability and provides symptomatic relief in conditions characterized by abnormal nerve activity, particularly restless legs syndrome and postherpetic neuralgia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: